(Q37872357)

24 August 2017

1 reference

title

How much is the life of a cancer patient worth? A pharmaco-economic perspective (English)

1 reference

24 August 2017

1 reference

S Simoens

1

1 reference

24 August 2017

M Dooms

series ordinal

2

1 reference

24 August 2017

publication date

24 August 2010

1 reference

Journal of Clinical Pharmacy and Therapeutics

24 August 2017

published in

1 reference

24 August 2017

volume

36

1 reference

24 August 2017

issue

3

1 reference

24 August 2017

page(s)

249-256

1 reference

Review of NICE's recommendations, 1999-2005.

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2010.01181.X

National Institute for Clinical Excellence and its value judgments

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2010.01181.X

10 years of NICE: still growing and still controversial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2010.01181.X

Pharmaceutical risk-sharing agreements

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2010.01181.X

Cost-effectiveness of primary versus secondary prophylaxis with pegfilgrastim in women with early-stage breast cancer receiving chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2010.01181.X

Prices and availability of biopharmaceuticals: an international comparison.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2010.01181.X

Is the current approach to reviewing new drugs condemning the victims of rare diseases to death? A call for a national orphan drug review policy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2010.01181.X

10.1111/J.1365-2710.2010.01181.X

21 January 2018

Identifiers

DOI

1 reference

24 August 2017

1 reference